FDA grants priority review for Vertex drug

FDA grants priority review for Vertex drug

Vertex Pharmaceuticals Inc. said that the Food and Drug Administration has granted its request for an expedited review of its potential Hepatitis C treatment.

The FDA’s standard review time for a drug candidate is 10 months. But Cambridge-based Vertex said in a press release that the FDA has agreed to review Telaprevir in six months, with a target review date set for May 23.

As the release noted, the FDA grants priority reviews to drug candidates that offer major advances in treatment or provide a treatment where no adequate therapy exists.

Vertex added that Telaprevir has also been granted a priority review by Canadian drug regulators.

Leave a Reply

Your email address will not be published. Required fields are marked *

Compare